Hospital-Treated Gram-Negative Infections – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of hospital-treated gram-negative infections (HT–GNIs) comprises epidemiological estimates of nine types of infections: urinary tract infections, bloodstream infections (BSIs), complicated intra-abdominal infections (cIAIs), complicated skin and skin structure infections (cSSSIs), surgical-site infections, nosocomial pneumonia, hospital-acquired pneumonia (HAP), healthcare-acquired pneumonia, and ventilator-associated pneumonia in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of HT–GNIs for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s HT–GNI forecast will answer the following questions:

• Of all people diagnosed with GNIs, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HT–GNIs over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts more than 200 HT–GNI patient populations, including the following:

• Diagnosed gram-negative BSI hospitalization events due to E.coli.
• Diagnosed gram-negative UTI hospitalization events due to Pseudomonas spp.
• Diagnosed BSI hospitalization events due to other gram-negative bacteria.
• Diagnosed cIAI hospitalization events due to E.coli.
• Diagnosed HAP hospitalization events due to cephalosporin-susceptible Klebsiella spp.
• Diagnosed cSSSI hospitalization events due to fluoroquinolone-resistant Acinetobacter spp.

Note: Coverage may vary by country and region.